Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

Several lots of intravenous and subcutaneous immune globulin have been voluntarily withdrawn by the manufacturers as a precautionary measure due to increased reports of allergic/hypersensitivity type ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

Years of research involving hundreds of thousands of children have found no link between autism and vaccines. HealthDay News — The US Centers for Disease Control and Prevention (CDC) is preparing to ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

“Our trial showed that treating male partners with a week of oral metronidazole and topical clindamycin, together with treatment of women, resulted in a lower rate of recurrence of bacterial vaginosis ...

The survey revealed that 18% of young adults aged 18 to 29 years needed to borrow money to pay health care costs. Adults aged 30 to 49 years reported similar rates. However, only 9 and 2% of Americans ...

OKYO Pharma has filed a Fast Track designation application with the Food and Drug Administration (FDA) for urcosimod in the treatment of neuropathic ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The Launch-HTN trial (ClinicalTrials.gov Identifier: ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...